The goal of this project is to develop methodology to prime cytotoxic T lymphocyte (CTL) immunity to Human Immunodeficiency Virus and other pathogens using nonliving vaccines. Currently, optimal methods do not exist to prime this critical form of immunity to viruses. The development of efficacious vaccines to these pathogens would be of great benefit to both man and animals. Two novel approaches are being taken. The first approach will prime CTL's with peptides by exploiting the observation that peptides associate with class I Major Histocompatibility Complex (MHC) molecules upon reassociation of beta2-microglobulin. Methods will be developed for introducing peptides and beta2-microglobulin in-vivo in a manner that will form peptide-class I MHC molecule complexes and prime CTL's. The second approach will prime CTL's with intact proteins by exploiting the observation that native antigens can be presented to CTL's by a specialized antigen-presenting cell resident in normal tissues. We will develop suitable methods for enhancing antigen entry into this pathway of antigen-presentation. These approaches will be developed for vaccines in association with murine, and then human class I MHC molecules.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI031337-03
Application #
3146304
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1991-03-01
Project End
1996-02-28
Budget Start
1993-03-01
Budget End
1994-02-28
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Vidard, L; Kovacsovics-Bankowski, M; Kraeft, S K et al. (1996) Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 156:2809-18
Falo Jr, L D; Kovacsovics-Bankowski, M; Thompson, K et al. (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1:649-53
Kovacsovics-Bankowski, M; Rock, K L (1995) A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243-6
Kovacsovics-Bankowski, M; Rock, K L (1994) Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines. Eur J Immunol 24:2421-8
Rock, K L; Rothstein, L; Gamble, S et al. (1993) Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol 150:438-46
Kovacsovics-Bankowski, M; Clark, K; Benacerraf, B et al. (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 90:4942-6
Rock, K L; Fleischacker, C; Gamble, S (1993) Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. J Immunol 150:1244-52
Falo Jr, L D; Colarusso, L J; Benacerraf, B et al. (1992) Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc Natl Acad Sci U S A 89:8347-50
Grant, E P; Rock, K L (1992) MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J Immunol 148:13-8